8 / 9
Page 29
Notes:
allied
academies
Case Reports in Surgery and Invasive Procedures | Volume 3
March 11-12, 2019 | London, UK
Biomarkers
Plastic and Cosmetic Surgery
International Conference on
International Conference on
Joint Event
&
AMCAR combined with PSA as prognosis biomarker to improve the prediction of prostate cancer
progression
Shian Ying Sung, Yen Kuan Lin
and
Yun Yen
Taipei Medical University, Taiwan
S
erum samples offer unique opportunities for early diagnosis
of clinical conditions. Previously reports indicated the
combination of serum biomarkers improve the precision
detection of cancer progression, include prostate cancer.
Currently, standard detection of serumproteins purely based on
the technology of antigen and antibody interaction. Therefore,
the precision of serum markers was determined by the quality
of antibodies. Here, we show that detection of enzyme activities
of AMCAR, the original biological function of serum biomarkers,
provides a better accuracy and precision of diagnosis and
prognosis prediction. Prostate cancer patient serumwas used to
compare the accuracy of PSA with or without enzyme activities
as the biomarker. Electrochemical platform prototype was used
for the AMCAR testing. AMCAR electrochemical enzyme system
showed higher of specificity when compared to clinical PSA
data. The specificity of AMCAR is 53% in average. The specificity
of PSA is 40% in average. In addition, accuracy of AMCAR is
higher than PSA alone, in which they are 52.7% and 51% of
accuracy, respectively. In addition, the combination of PSA and
AMCAR showed more than 70% in accuracy. When we combine
PSA, fPSA/PSA and AMCAR, the accuracy reached to the 76%
in average, suggested the important to use the combination
testing for future platform development. The results indicated
with the combination of enzyme activities we could increase the
accuracy to detect prostate cancer when compared PSA only. In
conclusion, our results highlight the medically relevant potential
of determining enzyme activities in cancer patient serum and
possibly other body fluids. Thus, proteins biological function
rather serum concentration is a new class of liquid biopsy that
promise to serve as useful clinical biomarkers.
Speaker Biography
Shian Ying Sung has completed his PhD from Virginia Commonwealth University, USA in
2000. He then went to Emory University as young investigator and instructors. He is the
director of Joint Clinical Research Center and associate professor of The PhD Program for
Translational Medicine, Taipei Medical University, Taipei, Taiwan. His lab has expertise and
extensive experience in 3D modeling of tumor and microenvironment interaction. His
publications are in outstanding journals and has been working on prostate cancer tumor
microenvironment for over 18 years. Currently, there are 3 to 4 international collaborations
ongoing, includes Kobe University, Cedars Sinai Medical Center, Case Western Reserve
University and University of Malaya. He is currently the chair of Regional Asia Clinical Trial
Association (REACTA) and hosting the REACTA annual Meeting in Taipei.
e
:
ssung@tmu.edu.tw